Effect of Lugol's Solution in the Patients With Graves' Disease
Effect of Lugol's Solution in the Patients With Graves' Disease
Context: Although some of endocrine surgeons administer Lugol's solution to decrease thyroid
 gland vascularity, there is still no agreement on its effectiveness.

 Objective: The aims of this clinical trial are to evaluate thyroid blood flow and microvessel
 density in the patients with Graves' disease according to the Lugol's solution treatment
 preoperatively.

 Design: Retrospective clinical trial. Setting: A tertiary referral center. Method: Thirty-six
 patients were randomly assigned to preoperative medication with Lugol's solution. Patients in
 group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas
 patients in group 2 (n=19) didn't receive it.

 Main Outcome Measures: Blood flow through the thyroid arteries of patients with Graves'
 disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was
 assessed immunohistochemically and Western blot analysis using the level of expression of
 CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all
 patients.
Thirty-six patients were randomly assigned to preoperative medication with Lugol's solution.
 Patients in group 1 (n=17) received Lugol's solution for 10 days before surgical
 intervention, whereas patients in group 2 (n=19) didn't receive it. Blood flow through the
 thyroid arteries of patients with Graves' disease was measured by color flow Doppler
 ultrasonography. The microvessel density (MVD) was assessed immunohistochemically and Western
 blot analysis using the level of expression of CD-34 in thyroid tissue. The thyroid gland's
 weight and blood loss were measured in all patients.
Inclusion Criteria:

 -  Graves disease

 Exclusion Criteria:

 -  Anticoagulant usage,

 -  Previous thyroid operation,

 -  Refused to participate in this study.